Search
Hexaminolevulinate
go.drugbank.com/drugs/DB06261ApprovedInvestigationalFood and Drug Administration (FDA) granted approval for hexaminolevulinate hydrochloride (Cysview for Intravesical Solution, Photocure ASA), as an optical imaging agent for use in combination with the
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian
Remimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigational[A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722]
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnIn April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]
Methylene blue
go.drugbank.com/drugs/DB09241ApprovedInvestigationalThe intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia.
Bremelanotide
go.drugbank.com/drugs/DB11653Approved[A179689] Bremelanotide was granted FDA approval on 21 June 2019.[L9635]
Orlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalIt was approved by the FDA for use in combination with a reduced-calorie diet in 1999.
Lunacalcipol
go.drugbank.com/drugs/DB05024InvestigationalCTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vita...
Gelatin
go.drugbank.com/drugs/DB11242ApprovedInvestigationalVet approvedWithdrawn[A32426] Gelatin is generally recognized as safe (GRAS) by the FDA to be a non-hazardous food or food ingredient. … [L2110] The FDA withdrew its approval for the use of all intravenous drug products containing gelatin. Gelatin continues to be approved for other routes of administration.[L43942]
Moxidectin
go.drugbank.com/drugs/DB11431ApprovedInvestigationalVet approved[A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970]